Generic Sotylize Availability
Last updated on Jun 11, 2025.
Sotylize is a brand name of sotalol, approved by the FDA in the following formulation(s):
SOTYLIZE (sotalol hydrochloride - solution;oral)
-
Manufacturer: AZURITY
Approval date: October 22, 2014
Strength(s): 5MG/ML (5MG/ML) [RLD]
Is there a generic version of Sotylize available?
No. There is currently no therapeutically equivalent version of Sotylize available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sotylize. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Sotalol compositions and uses of the same
Patent 10,206,895
Issued: February 19, 2019
Inventor(s): Thomas H. Greg & Kiel Jeffrey S.
Assignee(s): ARBOR PHARMACEUTICALS, INC.The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
Patent expiration dates:
- April 1, 2034✓✓
- April 1, 2034✓✓
- April 1, 2034
-
Sotalol compositions and uses of the same
Patent 11,013,703
Issued: May 25, 2021
Inventor(s): Thomas; H. Greg et al.
Assignee(s): Arbor Pharmaceuticals, LLC (Atlanta, GA)The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
Patent expiration dates:
- April 1, 2034✓
- April 1, 2034
-
Sotalol compositions and uses of the same
Patent 11,850,222
Issued: December 26, 2023
Inventor(s): Thomas; H. Greg et al.
Assignee(s): ARBOR PHARMACEUTICALS, LLC (Atlanta, GA)The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
Patent expiration dates:
- November 19, 2034✓
- November 19, 2034✓
- November 19, 2034
-
Sotalol compositions and uses of the same
Patent 12,290,495
Issued: May 6, 2025
Inventor(s): Thomas; H. Greg et al.
Assignee(s): ARBOR PHARMACEUTICALS, LLC (Atlanta, GA)The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
Patent expiration dates:
- April 1, 2034✓
- April 1, 2034✓
- April 1, 2034
-
Sotalol compositions and uses of the same
Patent 9,724,297
Issued: August 8, 2017
Inventor(s): Thomas H. Greg & Kiel Jeffrey S.
Assignee(s): ARBOR PHARMACEUTICALS, INC.The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
Patent expiration dates:
- August 31, 2035✓✓
- August 31, 2035
More about Sotylize (sotalol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: group III antiarrhythmics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Cardizem
Cardizem is used to treat hypertension (high blood pressure), angina (chest pain), and heart rhythm ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Lanoxin
Lanoxin (digoxin) is used to treat congestive heart failure and atrial fibrillation. Includes ...
Multaq
Multaq (dronedarone) is an antiarrhythmic medication used to treat atrial fibrillation and atrial ...
Edoxaban
Edoxaban is used for atrial fibrillation, deep vein thrombosis, prevention of thromboembolism in ...
Propafenone
Propafenone is used for atrial fibrillation, atrial flutter, ventricular tachycardia ...
Flecainide
Flecainide is used for atrial fibrillation, atrial flutter, paroxysmal supraventricular ...
Rivaroxaban
Rivaroxaban is used for atrial fibrillation, cardiovascular risk reduction, congenital heart ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.